

Effect of Metformin on Healthy Live Birth in Women With Prediabetes

NCT06064669

Status	RECRUITING
Phase	Not Applicable
Sponsor	Shandong University
Enrollment	988 participants

Key Eligibility Criteria

Inclusion (3)

- Women who are diagnosed with prediabetes by ADA criteria, including either IFG, IGT, or HbA1C 5.7-6.4%.
- Women aged 20-40 years.
- Women who plan to undergo a new cycle of IVF, ICSI, or PGT-A.

Exclusion (8)

- Women who are diagnosed with diabetes according to the ADA criteria^{11,12}, which is meeting one of the following criteria: fasting plasma glucose ≥ 7.0 mmol/L, 2-h plasma glucose during 75-g OGTT ≥ 11.1 mmol/L, HbA1c $\geq 6.5\%$, or a random plasma glucose ≥ 11.1 mmol/L.
- Women who are taking medicine that interfere with glucose metabolism, such as metformin, oral anti-diabetic agents (sulfonylureas, glinides, thiazolidinediones, ~~α~~glycosidase inhibitors, GLP-1 receptor agonist, etc.), weight loss drugs (i.e. orlistat, etc.), glucocorticoids, and growth hormones within 2 months before enrollment.
- Women with un-corrected hyperthyroidism or hypothyroidism.
- Women with congenital or acquired abnormal uterine cavity including septate uterus, unicornous uterus, uterus duplex, and intrauterine adhesions.
- Women with a diagnosis of adenomyosis.
- ... and 3 more (see full listing online)

Locations (1 total)

Shandong University, Jinan, Shandong, China